Methods of treating cancer with an mTOR inhibitor

A method of treating a subject having a cancer, the method comprising:

• administering an initial dose of a compound to the subject;
• wherein the compound is:
• or a stereoisomer, tautomer, or oxepane isomer thereof, or pharmaceutically acceptable salt of any of the foregoing, in an amount of about 6 mg/week to about 25 mg/week for 1-5 weeks;
• and
• administering a subsequent dose of the compound, or a stereoisomer, tautomer, or oxepane isomer thereof, or pharmaceutically acceptable salt of any of the foregoing, in an amount of about 3 mg/week to about 12 mg/week
• wherein the cancer comprises a PIK3CA mutation, a PTEN mutation, a TSC1 mutation, a TSC2 mutation, or a combination thereof.